— Aurinia Pharmaceuticals (NASDAQ: AUPH) reported a third-quarter 2019 loss of $0.21 per share versus a loss of $0.15 per share expected.
— Revenue plunged by 39% to $230,000 versus $50,000 expected. The top line was hurt by nil contract revenue.
— Research and development expenses soared by 59% due to the manufacturing of voclosporin for commercial and investigational use. It also includes costs related to the Aurora 2 extension study and other expenses.
— As looking forward to results from the Aurora Phase 3 trial for kidney inflammation lupus nephritis by the end of this year, the company has been preparing for success by continuing to strengthen the Board.
— Looking ahead to 2020, and assuming positive results, Aurinia plans on submitting an NDA in the first half of 2020 and projects a commercial launch of voclosporin in early 2021 as a potential first-line treatment for lupus nephritis.
Most Popular
Does Unity Software (U) stock has more room to run?
Last month, the IPO market was in a full swing. IPOs of Snowflake (NYSE: SNOW) and JFROG (NASDAQ: FROG) had an impressive opening day in September, the former creating a
PepsiCo (PEP): Steady snacking habits amid pandemic drive strong quarter for beverage giant
PepsiCo Inc. (NASDAQ: PEP) beat market expectations on both revenue and earnings for the third quarter of 2020. The company saw the momentum continue in its snacks business while the
Does the virus-driven boom make Electronic Arts (EA) a good investment?
With more and more people turning to virtual entertainment sources, amid the virus-related movement restrictions, video game publishers like Electronic Arts (NASDAQ: EA) are witnessing unusually high demand. Not surprisingly,
One thought on “Aurinia Pharmaceuticals (NASDAQ: AUPH): Q3 2019 Earnings Snapshot”
Comments are closed.